• 1
    Ross SD, Allen IE, Henry DH, Seaman C, Sercus B, Goodnough LT. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther. 2006; 28: 801-831.
  • 2
    Bohlius J, Langensiepen S, Schwarzer G, et al. Erythropoietin for patients with malignant disease [serial online]. Cochrane Database Syst Rev. 2004;( 3):CD003407.
  • 3
    Bohlius J, Wilson J, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer [serial online]. Cochrane Database Syst Rev. 2006;( 3):CD003407.
  • 4
    Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002; 95: 888-895.
  • 5
    Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer a meta-analysis of randomized trials. Lancet. 2009; 373: 1532-1542.
  • 6
    Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer. 2010; 102: 301-315.
  • 7
    Newland AM, Black CD. Tumor progression associated with erythropoiesis-stimulating agents. Ann Pharmacother. 2008; 42: 1865-1870.
  • 8
    Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008; 299: 914-924.
  • 9
    Jemal A, Siegel R, Ward E, Yongping H, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin. 2009; 59: 225-249.
  • 10
    Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009; 27: 1419-1425.
  • 11
    Cornes P, Boiangiu I. The role of epoetin beta in the treatment of anemia in patients with gynaecological malignancies. Anticancer Res. 2007; 27( IB): 513-522.
  • 12
    World Health Organization (WHO). WHO Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation. WHO Technical Report Series 894. Geneva, Switzerland: World Health Organization; 2000.
  • 13
    Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet. 2003; 362: 1255-1260.
  • 14
    Machtay M, Pajak TF, Suntharalingram M, et al. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). Int J Radiat Oncol Biol Phys. 2007; 69: 1008-1017.
  • 15
    Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005; 23: 5960-5972.
  • 16
    Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002; 94: 1211-1220.
  • 17
    Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001; 19: 2865-2874.
  • 18
    Witzig TE, Silberstein PT, Loprinzi C, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol. 2005; 23: 2606-2617.
  • 19
    Chang J, Couture F, Young S, et al. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol. 2005; 23: 2597-2605.
  • 20
    Savonije JH, van Groeningen CJ, van Bochove A, et al. Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level, and survival during platinum-based chemotherapy: results of a multicenter randomized controlled trial. Eur J Cancer. 2005; 41: 1560-1569.
  • 21
    Temkin SM, Hellmann M, Serur E, Lee Y-C, Abulafia O. Erythropoietin administration during primary treatment for locally advanced cervical carcinoma is associated with poor response to radiation. Int J Gynecol Cancer. 2006; 16: 1855-1861.
  • 22
    Thomas G, Ali S, Hoebers FJP, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin versus above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol. 2008; 108: 317-325.
  • 23
    Wilkinson PM, Antonopoulos M, Lahousen M, Lind M, Kosmidis P; EPO-INT-45 Study Group. Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial. Br J Cancer. 2006; 94: 947-954.
  • 24
    Swift S, Ellison AR, Kassner P, et al. Absence of functional EpoR expression in human tumor cell lines. Blood. 2010; 115: 4254-4263.
  • 25
    Sinclair AM, Coxon A, McCaffery I, et al. Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood. 2010; 115: 4264-4272.
  • 26
    Okazaki T, Ebihara S, Asada M, et al. Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor bearing mice by enhancing angiogenesis. Neoplasia. 2008; 10: 932-939.